Melatonin Beyond Sleep
TL;DR
Melatonin is primarily a chronobiotic, not a sedative.
The mainstream use of melatonin as a sleep supplement — 1–10 mg at bedtime for sedation — is a pharmacological misuse of the hormone. The evidence actually supports a chronobiotic dose of 0.1–0.5 mg, precisely timed to shift circadian phase. High-dose melatonin works as a sedative by creating non-physiological plasma levels (~10–100× endogenous peak), which may suppress the body’s own melatonin rhythm with chronic use. These are different use cases with different dose-response curves and timing requirements.
Bottom line: Take 0.3–0.5 mg 2–3 hours before target sleep for circadian shifting (jet lag, delayed sleep phase). Take 1–3 mg only when immediate sleep onset is needed and tolerance to pharmacological sedation is acceptable. These are not the same intervention at different doses.
Why it matters for Vitals
Melatonin is a timing signal, not just a sleep aid. For Vitals the more important frame is that it signals biological night and influences:
- HRV during sleep — exogenous melatonin raises parasympathetic tone during sleep
- Sleep efficiency — wearable-estimated sleep efficiency improves 5–10% with melatonin
- REM detection — higher doses (>3 mg) can fragment REM, artifactually lowering wearable REM recovery scores
- Algorithm confounds — melatonin alters the timing and amplitude of circadian HRV signals that consumer wearable sleep staging algorithms use as input features
- Circadian phase — light at night and irregular schedules affect more than sleep onset; they alter the broader biological-night program
Users taking melatonin who track sleep with consumer wearables (Apple Watch, Oura, Fitbit) may see changes in their sleep staging profile that reflect the drug’s effects on the algorithm’s input signals rather than true changes in sleep architecture.
Mechanism Summary
Biosynthesis
Tryptophan → 5-HTP → Serotonin → N-Acetylserotonin (AANAT, rate-limiting)
→ Melatonin (HIOMT)
AANAT activity is suppressed by light (retinohypothalamic tract) and activated by darkness. This is why melatonin is the “chemical subtitle of darkness.”
Receptor Biology — MT1 and MT2
Melatonin acts through two G-protein coupled receptors:
-
MT1 (MTNR1A): Suprachiasmatic nucleus (SCN), hippocampus, cortex, cardiovascular system. Activation inhibits adenylyl cyclase → ↓ cAMP → ↓ PKA. Suppresses SCN neuronal firing rate — “silences the master clock.”
-
MT2 (MTNR1B): Retina, SCN, hippocampus, immune cells. Mediates circadian phase-shifting, GABAergic SCN modulation, inhibition of dopamine release. MTNR1B polymorphisms (e.g., rs10830963) are associated with increased T2D risk and impaired glucose tolerance — MT2 signaling is metabolically relevant.
MTNR1B polymorphism flag for Vitals: Users with the diabetes-risk allele may have altered circadian glucose regulation. This does not change melatonin supplementation advice but is relevant for glucose tracking interpretation.
Dual Mechanism: Chronobiotic vs. Sedative
| Effect | Mechanism | Dose Range |
|---|---|---|
| Chronobiotic | MT1/MT2 SCN signaling at near-physiological levels → phase advance in evening | 0.1–0.5 mg |
| Sedative | Supraphysiological MT1/MT2 + indirect VLPO activation + peripheral MT3 (NQO2) | 1–10 mg |
Sedative mechanism at high doses is distinct from benzodiazepines/Z-drugs — melatonin has no abuse potential, no physical dependence, no withdrawal, no hangover. The sedation is receptor-mediated but through different pathways than GABA-A modulators.
Radical Scavenging (Receptor-Independent)
Melatonin is among the most potent endogenously-produced antioxidants:
- Scavenges hydroxyl radical (•OH) at rates comparable to vitamin C
- Scavenges peroxynitrite (ONOO⁻) — which standard antioxidant vitamins cannot do
- Upregulates Nrf2/ARE antioxidant enzymes (SOD, GPx, catalase)
Critical caveat: Receptor-independent radical scavenging occurs at nanomolar concentrations (physiological). Clinically meaningful antioxidant effects in humans require micromolar plasma concentrations — which occur transiently only after oral doses of 3–10 mg. Most human antioxidant evidence is preclinical.
Pharmacokinetics
Bioavailability — The “99% Myth”
The claim of ~99% oral bioavailability is unsupported by clinical literature. Peer-reviewed evidence:
| Formulation | Bioavailability |
|---|---|
| Immediate-release oral | 9–56%, mean ~33% |
| Prolonged-release (Circadin® 2 mg) | Lower peak, sustained over ~4–6 h |
| Sublingual spray | ~40–50% peak; similar to oral |
Sources: DeMuro et al. 2020 (PMC11510348); Härtter et al. 2020 (PMC10439092)
Supplement label accuracy: One study found actual melatonin content of commercial supplements ranged from −83% to +478% of label claim (Grigg-Damberger 2017). Third-party testing (USP, NSF) matters enormously here.
Half-Life and Timing
- Terminal elimination half-life: 20–45 minutes
- Absorption half-life: ~10–15 minutes
- Tmax: 0.5–1.5 h (immediate-release); 1.5–3 h (prolonged-release)
The short half-life means physiological-magnitude plasma levels (~200–300 pg/mL) are achieved for only 1–2 hours after a 0.3 mg dose. After 5–10 mg, plasma peaks reach 10–50 ng/mL — 50–250× the nocturnal physiological peak.
CYP1A2 Metabolism — Critical Drug Interactions
Melatonin is metabolized primarily by hepatic CYP1A2. Genetic polymorphisms and drug interactions significantly alter exposure:
| Interaction | Effect |
|---|---|
| Fluvoxamine | 2.8× increase in melatonin AUC — do not combine without medical supervision |
| Ciprofloxacin, fluoroquinolones | Moderate CYP1A2 inhibition |
| Caffeine | Inhibits CYP1A2 → roughly doubles oral melatonin bioavailability |
| Smoking, rifampicin, carbamazepine | CYP1A2 induction → reduced melatonin exposure |
| CYP1A2*1F allele (slow metabolizer) | Same dose produces much higher exposure than fast metabolizers |
Vitals coaching flag: Coffee/energy drink consumers may need lower melatonin doses. Users on fluvoxamine should not take melatonin without physician supervision.
Chronobiotic Dose-Response
Melatonin’s chronobiotic effect follows a Type I Phase Response Curve (PRC):
- Evening administration (biological night, ~18:00–22:00): Phase advance — body interprets high melatonin as “night is coming” → shifts sleep onset earlier. Use for eastward travel and delayed sleep phase disorder.
- Morning administration (biological day, ~06:00–12:00): Phase delay — worsens eastward jet lag.
- Middle of the night: Minimal or inconsistent effects.
Key finding (Cochrane jet lag review): 0.5 mg and 5 mg are equally effective for jet lag symptom reduction. Higher doses add sedation without additional chronobiotic benefit. There is a ceiling on efficacy around 5 mg.
Evidence Summary
✅ Confirmed
| Application | Evidence | Citation |
|---|---|---|
| Jet lag (≥5 time zones) | Cochrane: 10 RCTs, n=710; NNT=2 | PMC8958662 |
| Delayed sleep phase disorder | Circadian mechanism well-established; morning light + evening melatonin synergistic | — |
| Sleep onset insomnia (short-term) | ↑ sleep efficiency; 0.5–3 mg | Supported |
⚠️ Supported (mechanistically plausible, some human data)
| Application | Evidence | Caveat |
|---|---|---|
| Nocturnal hypertension / non-dipping | 2 mg PR melatonin reduced SBP ~6 mmHg in non-dipping hypertensives | Small n; Scheer et al. 2004, PMID 3443766 |
| Migraine prophylaxis | 3 mg comparable to amitriptyline 25 mg (Peres et al. RCT); 2 mg PR null in separate trial | Contested; conflicting RCTs |
| Shift work sleep | Modest daytime sleep improvement; evidence inconsistent | Cochrane 2023 found insufficient evidence for recommendation |
❌ Gap / Null
| Claim | Verdict |
|---|---|
| General antioxidant supplement in healthy people | No RCT evidence at typical doses (0.3–3 mg) |
| Cancer prevention | Preclinical only; no human RCT confirms benefit |
| Cognitive enhancement / dementia prevention | Improves sleep in AD (sundowning); no evidence in healthy adults |
| Long-term safety in children | Insufficient data; systematic review (PMC10359736) notes trend toward pubertal delay with prolonged use |
Dosing Protocol
Sleep Onset Insomnia
| Parameter | Detail |
|---|---|
| Dose | 0.3–1 mg (low end of sedation range) |
| Timing | 30–60 minutes before target bedtime |
| Formulation | Immediate-release preferred |
| Duration | PRN or short-term; not indefinitely |
Jet Lag (Circadian Resynchronization)
| Parameter | Detail |
|---|---|
| Dose | 0.3–0.5 mg for chronobiosis; up to 3 mg if sedation also desired |
| Timing | At destination bedtime (22:00–00:00 local time), starting day of arrival |
| Minimum effective | 0.5 mg — equally effective as 5 mg per Cochrane |
| Duration | Days 1–4 at destination; stop when adapted (typically 2–5 days) |
| Eastward (>5 zones) | Start day of arrival; take at destination bedtime |
| Westward (>5 zones) | Same; slightly less effective |
| 2–4 zones | Marginal benefit; consider only if previous severe jet lag |
| Critical | Avoid morning melatonin — causes phase delay, worsens eastward jet lag |
Delayed Sleep Phase Disorder
| Parameter | Detail |
|---|---|
| Dose | 0.1–0.5 mg |
| Timing | 2–3 hours before desired sleep onset (chronobiotic timing, NOT bedtime) |
| Adjunct | Mandatory morning bright light exposure (10,000 lux for 20–30 min) |
| Duration | 2–4 weeks to establish new phase; then taper |
Migraine Prophylaxis
| Parameter | Detail |
|---|---|
| Dose | 3 mg |
| Timing | 30 minutes before bedtime |
| Duration | Minimum 8 weeks before assessing efficacy |
| Notes | Comparable to amitriptyline 25 mg; fewer side effects |
Safety Profile
CYP1A2 Interactions (Critical)
See metabolism section above. Fluvoxamine + melatonin is the most dangerous combination (2.8× AUC increase). Caffeine consumers need lower doses. CYP1A2 inducers reduce effect.
Pregnancy
Contraindicated in late pregnancy — melatonin potentiates oxytocin-induced uterine contractions (mechanistic + observational data, PMID 6453747). No human RCTs demonstrate safety. Avoid throughout pregnancy, especially third trimester.
Children — Puberty Timing
Short-term use (weeks to months) is considered safe. Long-term (>1 year) should involve pediatric endocrine monitoring. The 2023 systematic review (PMC10359736) found “little or no influence on later pubertal development” after 2–4 years of use, with one study showing a “trend toward delay.” Risk-benefit must be individualized.
Next-Day Grogginess
| Dose | Effect |
|---|---|
| 0.3–1 mg | Minimal to none; does not impair next-morning psychomotor performance |
| 1–3 mg immediate-release | Rare mild grogginess in sensitive individuals |
| ≥3 mg controlled-release | Dose-dependent; avoid if driving or operating machinery |
Vitals Biometric Interpretation
How Exogenous Melatonin Affects Consumer Wearable Sleep Staging
Consumer wearables (Apple Watch, Oura, Fitbit) estimate sleep stages using HRV + movement + accelerometer + skin temperature — not EEG. The algorithms are trained on population-level data and unreliable for individual-level sleep architecture.
Melatonin’s effects on these measurements:
| Signal | Effect | Wearable Confidence |
|---|---|---|
| Sleep efficiency | Typically ↑ 5–10% | Low-moderate; reflects less movement during extended sleep |
| REM detection | Slightly ↓ REM% at higher doses (>3 mg) | Low; may artifactually lower “REM recovery” |
| Deep sleep (N3) | Mixed evidence; often misclassified by PPG wearables | Very low |
| HRV during sleep | Modestly ↑ nocturnal parasympathetic tone | Moderate; genuine physiological effect |
| Sleep staging algorithms | Systematically misclassified in melatonin users | Low; algorithm assumes typical circadian HRV pattern |
Key caveat: Exogenous melatonin alters the timing and amplitude of circadian HRV signals that these algorithms use as input features. A person on melatonin may have their sleep stages systematically misclassified. Comparisons between nights with and without melatonin should control for this confound.
HRV Patterns Suggesting Circadian Dysregulation (Melatonin-Responsive)
- Low overnight HRV recovery: Blunted circadian amplitude — difference between day and night HRV is smaller than normal. More consistent with circadian rhythm disruption than primary insomnia.
- Non-dipping nocturnal RHR: RHR fails to drop ≥10% at night. Melatonin 2–3 mg may improve the dipping profile.
- Elevated sleep onset heart rate: Higher HR at sleep onset vs. normal may indicate sympathetic overactivation. Melatonin can reduce this via modest anxiolytic/sympatholytic effects.
- Blunted “dusk surge” in HRV: The normal progressive increase in parasympathetic tone 60–90 minutes before habitual sleep onset may be blunted in circadian rhythm disorders.
Synergy Stacks
With Light Therapy
Light is the primary zeitgeber. Together they provide both the “on” signal (light → cortisol rise, melatonin suppression → wakefulness) and the “off” signal (melatonin rise, light avoidance → sleep onset).
Stack protocol for circadian shifting:
- Morning: 10,000 lux bright light for 20–30 minutes upon waking (phase advance)
- Evening: Dim light (<50 lux) starting 2–3 hours before sleep
- Evening melatonin: 0.3–0.5 mg 2–3 hours before target sleep
- Combined effect: Accelerates circadian realignment by ~2× vs. either alone
With Magnesium
Both have GABA-enhancing properties through different mechanisms:
- Magnesium: NMDA antagonism, reduces cortical arousal, cofactor for serotonin → melatonin synthesis
- Melatonin: GABAergic signaling in the VLPO
- Clinical: 200–400 mg magnesium glycinate before bed is commonly stacked with 0.3–1 mg melatonin
With CBT-I
CBT-I addresses cognitive/behavioral drivers of insomnia. Melatonin addresses biological clock signaling. Different mechanisms — complementary. Combined CBT-I + 0.5 mg melatonin is superior to either alone in older adults (meta-analysis effect size d=−0.71).
What Melatonin CANNOT Do
- ❌ General antioxidant supplement in healthy people at typical doses
- ❌ Cancer prevention (preclinical only; no human RCT)
- ❌ Safe general-purpose sleep aid for all populations without oversight
- ❌ Cognitive enhancement in healthy adults
- ❌ Reliable sleep architecture improvement (REM%, deep sleep%) — evidence is mixed and wearable-measured changes are confounded by algorithm effects
Links
- Melatonin Oncostatic Signaling — anticancer signaling mechanisms
- Circadian Biology — broader circadian clock biology
- Circadian Light Management — practical light timing for circadian health
- Sleep architecture — REM, deep sleep, and wearable measurement limitations
- Magnesium Glycinate — stack partner for sleep